These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 30401749)

  • 1. Activation of hepatocyte growth factor/MET signaling initiates oncogenic transformation and enhances tumor aggressiveness in the murine prostate.
    Mi J; Hooker E; Balog S; Zeng H; Johnson DT; He Y; Yu EJ; Wu H; Le V; Lee DH; Aldahl J; Gonzalgo ML; Sun Z
    J Biol Chem; 2018 Dec; 293(52):20123-20136. PubMed ID: 30401749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant activation of hepatocyte growth factor/MET signaling promotes β-catenin-mediated prostatic tumorigenesis.
    Aldahl J; Mi J; Pineda A; Kim WK; Olson A; Hooker E; He Y; Yu EJ; Le V; Lee DH; Geradts J; Sun Z
    J Biol Chem; 2020 Jan; 295(2):631-644. PubMed ID: 31819003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen signaling is a confounding factor for β-catenin-mediated prostate tumorigenesis.
    Lee SH; Luong R; Johnson DT; Cunha GR; Rivina L; Gonzalgo ML; Sun Z
    Oncogene; 2016 Feb; 35(6):702-14. PubMed ID: 25893287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conditional deletion of the Pten gene in the mouse prostate induces prostatic intraepithelial neoplasms at early ages but a slow progression to prostate tumors.
    Kwak MK; Johnson DT; Zhu C; Lee SH; Ye DW; Luong R; Sun Z
    PLoS One; 2013; 8(1):e53476. PubMed ID: 23308230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The comprehensive role of E-cadherin in maintaining prostatic epithelial integrity during oncogenic transformation and tumor progression.
    Olson A; Le V; Aldahl J; Yu EJ; Hooker E; He Y; Lee DH; Kim WK; Cardiff RD; Geradts J; Sun Z
    PLoS Genet; 2019 Oct; 15(10):e1008451. PubMed ID: 31658259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deletion of the p16INK4a tumor suppressor and expression of the androgen receptor induce sarcomatoid carcinomas with signet ring cells in the mouse prostate.
    Lee DH; Yu EJ; Aldahl J; Yang J; He Y; Hooker E; Le V; Mi J; Olson A; Wu H; Geradts J; Xiao GQ; Gonzalgo ML; Cardiff RD; Sun Z
    PLoS One; 2019; 14(1):e0211153. PubMed ID: 30677079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression array analysis of the hepatocyte growth factor invasive program.
    Cecchi F; Lih CJ; Lee YH; Walsh W; Rabe DC; Williams PM; Bottaro DP
    Clin Exp Metastasis; 2015 Oct; 32(7):659-76. PubMed ID: 26231668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of HGF/SF-Met signaling in prostate adenocarcinoma cells: evidence for alternative mechanisms leading to a metastatic phenotype in Pr-14c.
    MacDougall CA; Vargas M; Soares CR; Holzer RG; Ide AE; Jorcyk CL
    Prostate; 2005 Jul; 64(2):139-48. PubMed ID: 15678502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis.
    Ma X; Ziel-van der Made AC; Autar B; van der Korput HA; Vermeij M; van Duijn P; Cleutjens KB; de Krijger R; Krimpenfort P; Berns A; van der Kwast TH; Trapman J
    Cancer Res; 2005 Jul; 65(13):5730-9. PubMed ID: 15994948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTEN reconstitution alters glioma responses to c-Met pathway inhibition.
    Goodwin CR; Lal B; Ho S; Woodard CL; Zhou X; Taeger A; Xia S; Laterra J
    Anticancer Drugs; 2011 Oct; 22(9):905-12. PubMed ID: 21654317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Klf5 deletion promotes Pten deletion-initiated luminal-type mouse prostate tumors through multiple oncogenic signaling pathways.
    Xing C; Ci X; Sun X; Fu X; Zhang Z; Dong EN; Hao ZZ; Dong JT
    Neoplasia; 2014 Nov; 16(11):883-99. PubMed ID: 25425963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PTEN loss and activation of K-RAS and β-catenin cooperate to accelerate prostate tumourigenesis.
    Jefferies MT; Cox AC; Shorning BY; Meniel V; Griffiths D; Kynaston HG; Smalley MJ; Clarke AR
    J Pathol; 2017 Dec; 243(4):442-456. PubMed ID: 29134654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells.
    Crosswell HE; Dasgupta A; Alvarado CS; Watt T; Christensen JG; De P; Durden DL; Findley HW
    BMC Cancer; 2009 Nov; 9():411. PubMed ID: 19939254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate epithelial Pten/TP53 loss leads to transformation of multipotential progenitors and epithelial to mesenchymal transition.
    Martin P; Liu YN; Pierce R; Abou-Kheir W; Casey O; Seng V; Camacho D; Simpson RM; Kelly K
    Am J Pathol; 2011 Jul; 179(1):422-35. PubMed ID: 21703421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SOCS1 inhibits migration and invasion of prostate cancer cells, attenuates tumor growth and modulates the tumor stroma.
    Villalobos-Hernandez A; Bobbala D; Kandhi R; Khan MG; Mayhue M; Dubois CM; Ferbeyre G; Saucier C; Ramanathan S; Ilangumaran S
    Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):36-47. PubMed ID: 27779203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of hepatocyte growth factor/scatter factor and met receptor signaling in hair follicle morphogenesis and cycling.
    Lindner G; Menrad A; Gherardi E; Merlino G; Welker P; Handjiski B; Roloff B; Paus R
    FASEB J; 2000 Feb; 14(2):319-32. PubMed ID: 10657988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plumbagin Inhibits Prostate Carcinogenesis in Intact and Castrated PTEN Knockout Mice via Targeting PKCε, Stat3, and Epithelial-to-Mesenchymal Transition Markers.
    Hafeez BB; Fischer JW; Singh A; Zhong W; Mustafa A; Meske L; Sheikhani MO; Verma AK
    Cancer Prev Res (Phila); 2015 May; 8(5):375-86. PubMed ID: 25627799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conditional expression of the androgen receptor induces oncogenic transformation of the mouse prostate.
    Zhu C; Luong R; Zhuo M; Johnson DT; McKenney JK; Cunha GR; Sun Z
    J Biol Chem; 2011 Sep; 286(38):33478-88. PubMed ID: 21795710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. c-met proto-oncogene expression in benign and malignant human prostate tissues.
    Pisters LL; Troncoso P; Zhau HE; Li W; von Eschenbach AC; Chung LW
    J Urol; 1995 Jul; 154(1):293-8. PubMed ID: 7539865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of the tumor suppressor, Tp53, enhances the androgen receptor-mediated oncogenic transformation and tumor development in the mouse prostate.
    He Y; Johnson DT; Yang JS; Wu H; You S; Yoon J; Lee DH; Kim WK; Aldahl J; Le V; Hooker E; Yu EJ; Geradts J; Cardiff RD; Sun Z
    Oncogene; 2019 Sep; 38(38):6507-6520. PubMed ID: 31358900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.